Pharmacokinetics of Tildrakizumab (MK ‐3222), an Anti‐IL‐23 Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Subjects

This article is protected by copyright. All rights reserved.

Source: Basic and Clinical Pharmacology and Toxicology - March 6, 2018 Category: Drugs & Pharmacology Authors: Sauzanne Khalilieh, Peter Hodsman, Christine Xu, Anjela Tzontcheva, Shirley Glasgow, Diana Montgomery Tags: Original Article Source Type: research